Double-digit revenue increases in all its business segments propelled proton therapy developer Ion Beam Applications (IBA) to higher financial ground in the company's first quarter.
For the quarter (end-March 31), total revenues increased 13% to 73.3 million euros ($79.9 million U.S.), with sales of proton therapy and accelerators contributing a 12% gain and 58.7 million euros ($64 million). The company's dosimetry business segment advanced 19% in the first quarter to 14.6 million euros ($15.9 million).
The company also revised its forecast to 10% to 12% revenue growth for 2017 and 13% revenue growth for 2018.
